Rev­o­lu­tion inks up to $2B 'flex­i­ble' fund­ing deal to ad­vance RAS in­hibitor pipeline

Rev­o­lu­tion Med­i­cines has signed a “flex­i­ble fund­ing agree­ment” with Roy­al­ty Phar­ma for up to $2 bil­lion that should sup­port it through late-stage de­vel­op­ment of its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER